Home / Psoriasis / Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

Brief Summary:
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: risankizumab Drug: secukinumab Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment :310 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title:A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Actual Study Start Date :May 8, 2018
Estimated Primary Completion Date :November 29, 2019
Estimated Study Completion Date :June 25, 2020
Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

U.S. FDA Resources

About

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts …

Leave a Reply

Your email address will not be published. Required fields are marked *